Cargando…
Values for preventing influenza-related morbidity and vaccine adverse events in children
BACKGROUND: Influenza vaccination recently has been recommended for children 6–23 months old, but is not currently recommended for routine use in non-high-risk older children. Information on disease impact, costs, benefits, risks, and community preferences could help guide decisions about which age...
Autores principales: | Prosser, Lisa A, Bridges, Carolyn Buxton, Uyeki, Timothy M, Rêgo, Virginia H, Ray, G Thomas, Meltzer, Martin I, Schwartz, Benjamin, Thompson, William W, Fukuda, Keiji, Lieu, Tracy A |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1083419/ https://www.ncbi.nlm.nih.gov/pubmed/15780143 http://dx.doi.org/10.1186/1477-7525-3-18 |
Ejemplares similares
-
Health Benefits, Risks, and Cost-Effectiveness of Influenza Vaccination of Children
por: Prosser, Lisa A., et al.
Publicado: (2006) -
Cost-effectiveness of increased influenza vaccination uptake against readmissions of major adverse cardiac events in the US
por: Peasah, Samuel K., et al.
Publicado: (2019) -
Community-Based Values for 2009 Pandemic Influenza A H1N1 Illnesses and Vaccination-Related Adverse Events
por: Lavelle, Tara A., et al.
Publicado: (2011) -
Cost-Effectiveness of 2009 Pandemic Influenza A(H1N1) Vaccination in the United States
por: Prosser, Lisa A., et al.
Publicado: (2011) -
Lack of Evidence for Human-to-Human Transmission of Avian Influenza A (H9N2) Viruses in Hong Kong, China 1999
por: Uyeki, Timothy M., et al.
Publicado: (2002)